Filing Details
- Accession Number:
- 0001209191-15-033248
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-08 19:25:24
- Reporting Period:
- 2015-04-06
- Filing Date:
- 2015-04-08
- Accepted Time:
- 2015-04-08 19:25:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1215126 | G Margaret Mcglynn | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-04-06 | 12,500 | $53.85 | 13,588 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-04-06 | 2,200 | $117.14 | 11,388 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-04-06 | 6,000 | $118.32 | 5,388 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-04-06 | 3,900 | $118.97 | 1,488 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-04-06 | 400 | $119.78 | 1,088 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Acquisiton | 2015-04-06 | 12,500 | $0.00 | 12,500 | $53.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,500 | 2021-05-31 | No | 4 | A | Direct |
Footnotes
- Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $117.14 (range $116.56 to $117.53).
- Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $118.32 (range $117.64 to $118.63).
- Open market sales reported on this line occurred at a weighted average price of $118.97 (range $118.64 to $119.58).
- Open market sales reported on this line occurred at a weighted average price of $119.78 (range $119.72 to $119.95).
- Fully vested.
Billionaire Hedge Funds
